EGFR (Ab-678) Antibody

What is the target epitope of EGFR (Ab-678) Antibody and how does it affect detection applications?

EGFR (Ab-678) Antibody targets a peptide sequence around amino acids 676-680 (K-R-T-L-R) derived from Human EGFR. This epitope is located in a specific region of the EGFR protein that enables detection of endogenous levels of total EGFR protein. The antibody was produced by immunizing rabbits with a synthetic peptide conjugated to KLH (Keyhole Limpet Hemocyanin), which enhances immunogenicity . This specific epitope selection has important implications for experimental design, as it allows detection of EGFR regardless of phosphorylation status, making it suitable for total EGFR quantification across various experimental conditions .

For most accurate detection, researchers should consider that this C-terminal epitope will be present in most EGFR variants except those with C-terminal truncations. When monitoring receptor dynamics, this antibody can be paired with phospho-specific antibodies to distinguish between total and activated EGFR populations in the same experimental system.

What species reactivity is confirmed for EGFR (Ab-678) Antibody and how can cross-species applications be validated?

EGFR (Ab-678) Antibody has confirmed reactivity against human, mouse, and rat EGFR . This cross-species reactivity is attributable to the conservation of the target epitope sequence across these species. When designing experiments using non-validated species, preliminary validation should include:

• Western blotting with appropriate positive controls from the species of interest

• Signal comparison with established EGFR-expressing tissues/cell lines from validated species

• Peptide competition assays to confirm specificity in the new species

For comparative studies across species, researchers should note that while the epitope is conserved, binding affinity may vary slightly between species due to differences in surrounding amino acids that could affect epitope accessibility. Quantitative comparisons between species should be interpreted with this consideration in mind.

What are the validated applications for EGFR (Ab-678) Antibody and their optimization strategies?

EGFR (Ab-678) Antibody is primarily validated for Western blotting (WB) with a recommended dilution range of 1:500 to 1:1000 . Experimental evidence demonstrates successful detection of the 175 kDa EGFR protein in cell extracts from HUVEC and MDA cells .

Other potential applications include ELISA, immunohistochemistry (IHC), and immunoprecipitation (IP) . For immunoprecipitation protocols, approximately 10 μL of antibody should be used with 25 μL of Protein A-agarose beads and 1.0 mL of lysate containing approximately 1.0 mg of total protein .

Application-specific optimization strategies include:

• For Western blotting: Use 8% polyacrylamide gels for optimal separation of high molecular weight EGFR (175 kDa); transfer to PVDF membranes; block with 5% low-fat milk in TTBS

• For IHC: Begin with 2.5 μg/mL concentration; include antigen retrieval steps; validate with known EGFR-positive controls like epidermis or placenta tissues

• For IP: Pre-clear lysates to reduce background; perform multiple washes with lysis buffer to remove non-specifically bound proteins

How can I design robust controls for EGFR (Ab-678) Antibody experiments?

Designing robust controls for EGFR antibody experiments requires a multi-layered approach:

• Positive Controls: Include cell lines with well-characterized EGFR expression:

  • A431 cells (human epidermoid carcinoma line) overexpress EGFR and serve as the gold standard positive control

  • HUVEC cells express moderate EGFR levels and have been validated specifically with EGFR (Ab-678) Antibody

  • Normal human epidermis (keratinocytes) and placenta tissue express significant EGFR levels and can serve as tissue-based positive controls

• Negative Controls:

  • Antibody validation: Omit primary antibody to assess secondary antibody background

  • Signal specificity: Pre-incubate antibody with immunizing peptide (aa 676-680) to block specific binding

  • Biological validation: Include EGFR-knockdown samples (siRNA/shRNA-treated) or EGFR-negative cell lines

• Technical Controls:

  • Loading controls: Include housekeeping proteins like GAPDH, β-actin, or α-tubulin for normalization

  • Transfer efficiency: Use Ponceau S staining to confirm efficient transfer of high molecular weight proteins

  • Molecular weight verification: Confirm band appears at expected size (175 kDa for full-length EGFR)

• Treatment Controls:

  • Include EGF-stimulated samples to increase EGFR activation (detected with phospho-specific antibodies)

  • Include tyrosine kinase inhibitor (TKI) treated samples to decrease EGFR phosphorylation

  • Compare wild-type vs. mutant EGFR-expressing samples when studying activation mechanisms

These comprehensive controls enable confident interpretation of results and troubleshooting of potential issues in experimental design.

How do molecular dynamics (MD) simulations complement antibody-based detection of EGFR structure and function?

Molecular dynamics (MD) simulations provide complementary insights to antibody-based approaches for understanding EGFR structure-function relationships:

• Temporal resolution advantages: While antibodies like EGFR (Ab-678) capture static snapshots of protein states, MD simulations reveal dynamic transitions between conformations. Modern MD simulations can capture microsecond-scale events relevant to EGFR conformational changes and activation mechanisms .

• Structural insight integration:

  • X-ray crystallography and antibody epitope mapping provide static structural information

  • MD simulations add dynamics to these structures, revealing transient states and energy barriers

  • Combined approaches offer superior understanding of EGFR's allosteric mechanisms

• Specific research applications:

  • Receptor dimerization dynamics: MD simulations reveal subtle conformational changes during dimerization that antibodies cannot detect

  • Drug binding mechanisms: Simulations can predict how mutations alter drug binding before experimental validation

  • Allosteric communication: MD identifies long-range communication networks within EGFR structure

• Methodological workflow integration:

  • Initial protein characterization with antibodies like EGFR (Ab-678)

  • Structural determination via X-ray crystallography

  • MD simulation to explore conformational dynamics

  • Experimental validation of simulation predictions using site-specific antibodies

Advanced computational approaches like enhanced-sampling algorithms further extend simulation timescales to hundreds of microseconds, enabling observation of large-scale EGFR conformational changes previously inaccessible to computational methods .

How can I distinguish between total EGFR and phosphorylated EGFR in my experimental system?

Distinguishing between total and phosphorylated EGFR requires strategic experimental design:

• Antibody selection strategy:

  • Use EGFR (Ab-678) Antibody to detect total EGFR regardless of activation state

  • Employ phospho-specific antibodies targeting key sites (pY1068, pY1173, pS1026, pS1071) to detect activated forms

  • Calculate phosphorylated/total ratios to quantify activation levels across experimental conditions

• Western blot approaches:

  • Parallel blots: Run identical samples on multiple gels, then probe separate membranes with total and phospho-specific antibodies

  • Stripping and reprobing: After detecting one form, strip the membrane and reprobe for the other (note: may reduce sensitivity)

  • Dual-color detection: Use secondary antibodies with different fluorescent conjugates to simultaneously detect total and phosphorylated EGFR on the same membrane

• Functional validation experiments:

  • EGF stimulation (1-100 ng/mL, 5-15 minutes): Should increase phosphorylation without changing total EGFR initially

  • Prolonged EGF exposure (>30 minutes): Should decrease total EGFR due to internalization and degradation

  • TKI treatment (e.g., gefitinib): Should reduce phosphorylation without immediate effects on total EGFR levels

• Subcellular localization analysis:

  • Use immunofluorescence with total EGFR and phospho-specific antibodies to track receptor trafficking

  • Membrane fractionation followed by Western blotting to quantify receptor redistribution upon activation

  • Phosphorylated EGFR should show progressive internalization following stimulation

These approaches provide complementary information about EGFR dynamics, enabling robust interpretation of receptor activity in response to experimental manipulations.

What strategies can minimize cross-reactivity concerns when using EGFR antibodies in multi-protein analyses?

When conducting multi-protein analyses with EGFR (Ab-678) Antibody, several strategies can minimize cross-reactivity issues:

• ErbB family discrimination:

  • EGFR (ErbB1) shares structural homology with other ErbB family members (HER2/ErbB2, HER3/ErbB3, HER4/ErbB4)

  • Validate antibody specificity using cells expressing individual ErbB members

  • For multiplexing experiments, select antibodies targeting non-conserved epitopes across the ErbB family

• EGFR variant detection:

  • When studying cancers with potential EGFR mutations, confirm whether the Ab-678 epitope (aa 676-680) is preserved in variants of interest

  • EGFRvIII (common in glioblastoma) would be detected at ~140 kDa versus 175 kDa for wild-type

  • Use variant-specific antibodies alongside Ab-678 to distinguish specific mutations

• Technical cross-reactivity reduction:

  • Pre-adsorb antibody with common cross-reactive proteins if specific background is observed

  • Include peptide competition controls using the immunizing peptide sequence

  • Increase washing stringency (0.1-0.3% Tween-20) to reduce non-specific binding

• Comprehensive validation approach:

  • Orthogonal validation: Compare antibody results with mass spectrometry identification of immunoprecipitated proteins

  • Genetic validation: Use CRISPR knockout or siRNA knockdown samples to confirm signal specificity

  • Parallel validation: Test multiple antibodies targeting different EGFR epitopes

• Species-specific considerations:

  • For cross-species studies, validate antibody performance in each species independently

  • Note potential affinity differences between human, mouse, and rat samples

  • For immunoprecipitation followed by blotting, consider using species-specific secondary antibodies to minimize cross-reactivity

These methodological precautions ensure specific detection in complex experimental systems studying multiple proteins or EGFR variants.

How does EGFR mutation status affect antibody selection for cancer tissue analysis?

EGFR mutation status significantly impacts antibody selection strategy for cancer tissue analysis:

• Common EGFR mutations in cancer:

  • NSCLC: Exon 19 deletions, L858R point mutation (exon 21), T790M resistance mutation (exon 20)

  • Glioblastoma: EGFRvIII (deletion of exons 2-7)

  • Geographical variation: Higher frequency of activating mutations in Asian populations compared to European/Australian cohorts

• Antibody selection considerations:

  • Total EGFR detection: EGFR (Ab-678) Antibody targets aa 676-680, which is preserved in most clinically relevant mutations, making it suitable for detecting total EGFR regardless of mutation status

  • Mutation-specific detection: For specific mutations, use mutation-selective antibodies (e.g., anti-EGFRvIII, anti-L858R) alongside total EGFR antibodies

  • Size verification: EGFRvIII would appear at ~140 kDa vs. 175 kDa for wild-type EGFR in Western blots

• Research application strategy:

  • Discovery phase: Use antibodies like EGFR (Ab-678) to assess total EGFR expression levels

  • Mutation characterization: Employ mutation-specific antibodies or molecular techniques (PCR, sequencing)

  • Activation assessment: Combine with phospho-specific antibodies to determine if mutations lead to constitutive activation

• Methodological adaptations for mutant EGFR:

  • Optimize protein extraction protocols for membrane proteins to ensure complete solubilization

  • Include mutation-specific positive controls with known EGFR status

  • Consider tumor heterogeneity by analyzing multiple regions when possible

This strategic approach enables comprehensive characterization of EGFR status, distinguishing between expression levels, mutation status, and activation state in cancer research applications.

How can EGFR (Ab-678) Antibody be used in therapeutic response prediction studies?

EGFR (Ab-678) Antibody can be strategically employed in therapeutic response prediction studies through several methodological approaches:

• Baseline EGFR expression assessment:

  • Quantify pre-treatment EGFR levels in patient-derived xenografts or clinical samples

  • Correlate total EGFR expression with response to anti-EGFR therapies

  • Establish expression thresholds that predict therapeutic sensitivity or resistance

• EGFR imaging agent validation:

  • Support development of imaging agents like ABT-806i (¹¹¹In-labeled anti-EGFR antibody)

  • Compare immunohistochemistry results using EGFR (Ab-678) with radiolabeled antibody uptake

  • Validate target engagement in real-time compared to conventional archived tissue analysis

• Receptor occupancy studies:

  • Assess whether repeated doses of therapeutic antibodies affect subsequent binding of diagnostic antibodies

  • Monitor dynamic changes in accessible EGFR epitopes during treatment

  • Study shows stable EGFR expression in tumors after interval treatment with therapeutic antibodies

• Combining with predictive biomarkers:

  • For colorectal cancer: Integrate EGFR protein detection with RAS/BRAF mutation testing

  • For lung cancer: Combine with EGFR mutation analysis to stratify potential responders

  • For triple-negative breast cancer: Correlate with EGFR ligand expression (AREG/EREG) which has shown prognostic value

• Resistance mechanism investigation:

  • Monitor changes in total EGFR levels during acquired resistance development

  • Detect emergence of splice variants or mutations during treatment

  • Identify receptor trafficking alterations using subcellular fractionation followed by Western blotting

These approaches enable researchers to assess whether total EGFR levels alone or in combination with other biomarkers can effectively predict therapeutic responses to EGFR-targeted therapies.

What methodological approaches are optimal for studying EGFR-targeted antibody-mediated immune responses?

Studying EGFR-targeted antibody-mediated immune responses requires specialized methodological approaches:

• EGFR expression characterization:

  • Quantify surface EGFR levels using EGFR (Ab-678) Antibody in flow cytometry or immunohistochemistry

  • Assess heterogeneity of expression within tumor samples using immunofluorescence microscopy

  • Establish baseline expression in potential immune effector cells to avoid off-target effects

• Antibody-dependent cellular cytotoxicity (ADCC) assessment:

  • In vitro assays: Co-culture EGFR-expressing target cells with NK cells or macrophages in the presence of therapeutic antibodies

  • Flow cytometry analysis: Measure target cell death using annexin V/propidium iodide staining

  • Controls: Include EGFR (Ab-678) Antibody as a non-therapeutic control to distinguish immune from direct effects

• Complement-dependent cytotoxicity (CDC) evaluation:

  • Expose EGFR-expressing cells to therapeutic antibodies in the presence of complement

  • Measure cell lysis through release of intracellular enzymes (LDH assay) or membrane integrity dyes

  • Use EGFR expression levels determined by EGFR (Ab-678) Antibody to normalize results across cell lines

• Fc receptor engagement studies:

  • Use flow cytometry to measure binding of antibody-opsonized tumor cells to immune cells

  • Assess Fc receptor polymorphisms in relation to therapeutic efficacy

  • Develop bispecific antibodies targeting both EGFR and immune cell receptors

• In vivo immune response monitoring:

  • Characterize tumor-infiltrating lymphocytes before and after anti-EGFR therapy

  • Monitor changes in immune checkpoint molecule expression on EGFR-expressing cells

  • Assess changes in EGFR availability using immunohistochemistry with EGFR (Ab-678) Antibody following therapeutic antibody administration

These methodological approaches enable comprehensive investigation of how anti-EGFR therapeutic antibodies mediate immune responses beyond direct receptor signaling inhibition.

How do EGFR expression patterns differ across cancer types and how should detection methods be adapted?

EGFR expression patterns vary significantly across cancer types, requiring methodological adaptations for optimal detection:

• Cancer-specific expression patterns:

  • Non-small cell lung cancer (NSCLC): Higher EGFR expression in squamous vs. non-squamous subtypes, with greater therapeutic benefit from anti-EGFR mAb plus chemotherapy in squamous NSCLC

  • Triple-negative breast cancer (TNBC): EGFR overexpression in 13-76% of cases, with geographic variations in mutation frequency

  • Colorectal cancer (CRC): EGFR expression alone is not a strong predictor of anti-EGFR therapy response; EGFR ligand expression has greater prognostic value

  • Head and neck cancer: High EGFR expression correlates with treatment response; patients with highest ABT-806i uptake showed better clinical outcomes

• Methodological adaptations for different cancer types:

  a. NSCLC detection optimization:

  • Use membranous staining intensity for accurate quantification

  • Distinguish between wild-type and mutant EGFR using mutation-specific antibodies

  • Include positive controls with known mutation status

  b. TNBC analysis approach:

  • Combine protein detection (WB/IHC) with mRNA analysis (qPCR)

  • Screen for rare activating mutations considering geographic variations

  • Assess EGFR in context of other growth factor receptors

  c. CRC evaluation strategy:

  • Integrate EGFR protein detection with RAS/BRAF mutation testing

  • Assess EGFR ligand expression (AREG/EREG) alongside receptor levels

  • Use artificial intelligence-assisted IHC for standardized quantification

  d. Head and neck cancer assessment:

  • Quantify membrane-localized EGFR using subcellular fractionation

  • Consider EGFR as part of a broader receptor tyrosine kinase profile

  • Correlate with HPV status for prognostic interpretation

• Technical considerations across cancer types:

  • Standardize tissue processing and fixation protocols for consistent epitope preservation

  • Account for tumor heterogeneity by analyzing multiple regions

  • Consider circulating tumor cells as an alternative to tissue biopsies for longitudinal monitoring

These tailored approaches optimize EGFR detection across diverse cancer types while accounting for their unique biological and technical challenges.

What are the optimal protocols for using EGFR (Ab-678) Antibody in immunoprecipitation studies?

Optimized immunoprecipitation (IP) protocols for EGFR (Ab-678) Antibody require careful attention to several technical parameters:

• Reagent preparation and quantities:

  • Antibody amount: Use approximately 10 μL of EGFR (Ab-678) Antibody per IP reaction

  • Beads: Combine with 25 μL of Protein A-agarose beads (Protein A is optimal for rabbit IgG)

  • Lysate: Use 1.0 mL of lysate containing approximately 1.0 mg of total protein

• Detailed IP protocol:

  a. Cell lysis and pre-clearing:

  • Lyse cells in NP-40 buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40) with protease inhibitors

  • Pre-clear lysate with 25 μL Protein A-agarose alone for 1 hour at 4°C to reduce non-specific binding

  • Centrifuge at 14,000 × g for 10 minutes and transfer supernatant to new tube

  b. Antibody binding and precipitation:

  • Add EGFR (Ab-678) Antibody to pre-cleared lysate

  • Incubate with gentle rotation for 1-2 hours at 4°C

  • Add 25 μL Protein A-agarose beads and continue rotation overnight at 4°C

  c. Washing and elution:

  • Centrifuge at 1,000 × g for 5 minutes at 4°C

  • Wash immune complexes 3 times with lysis buffer (1 mL per wash)

  • Resuspend beads in 20-30 μL of 3X SDS-PAGE sample buffer

  • Heat at 95°C for 5 minutes to elute proteins

• Analysis of immunoprecipitated products:

  • Load approximately 15 μL of eluted sample per lane on an 8% polyacrylamide gel

  • Include input control (5% of pre-IP lysate) and IgG control (non-specific rabbit IgG)

  • Proceed with Western blotting using either the same antibody or another EGFR antibody targeting a different epitope

• Co-immunoprecipitation considerations:

  • For studying EGFR-interacting proteins, use gentler lysis conditions to preserve protein-protein interactions

  • When probing for interaction partners, use antibodies validated for Western blotting

  • Consider crosslinking approaches for transient interactions

These optimized protocols enable efficient isolation of EGFR and its complexes for downstream analysis of receptor interactions, modifications, and dynamics.

How can EGFR (Ab-678) Antibody support research on EGFR trafficking and internalization?

EGFR (Ab-678) Antibody can be strategically employed to investigate EGFR trafficking and internalization through several specialized methodological approaches:

• Subcellular fractionation studies:

  • Separate membrane, cytoplasmic, and nuclear fractions using differential centrifugation

  • Quantify EGFR distribution across fractions using Western blotting with EGFR (Ab-678) Antibody

  • Monitor changes in distribution following ligand stimulation or drug treatment

  • Validate fraction purity using compartment-specific markers (Na⁺/K⁺ ATPase for membrane, GAPDH for cytosol)

• Immunofluorescence microscopy protocols:

  • Fix cells at different time points after EGF stimulation (0, 5, 15, 30, 60 minutes)

  • Stain with EGFR (Ab-678) Antibody followed by fluorophore-conjugated secondary antibody

  • Co-stain with markers for early endosomes (EEA1), late endosomes (Rab7), or lysosomes (LAMP1)

  • Analyze colocalization to track receptor progression through endocytic compartments

• Surface biotinylation assays:

  • Label cell surface proteins with non-permeable biotin reagents

  • Stimulate with EGF for various time points

  • Isolate biotinylated (originally surface) proteins with streptavidin beads

  • Quantify internalized EGFR by Western blotting with EGFR (Ab-678) Antibody

• Pulse-chase analysis:

  • Metabolically label cells with ³⁵S-methionine/cysteine

  • Chase with unlabeled media +/- EGF stimulation

  • Immunoprecipitate EGFR at various time points using EGFR (Ab-678) Antibody

  • Autoradiography analysis reveals receptor synthesis, maturation, and degradation rates

• Live-cell imaging approaches:

  • Complement fixed-cell analysis with techniques like FRET (Fluorescence Resonance Energy Transfer)

  • FRET microscopy provides sub-nm measurements of receptor proximity when donor molecules transfer energy to nearby acceptors upon photon absorption

  • This enables precise tracking of receptor dimerization and clustering during internalization

These methodological approaches provide complementary data on EGFR trafficking dynamics in response to ligands, inhibitors, or genetic manipulations, enhancing understanding of receptor regulation in normal and pathological conditions.

What troubleshooting strategies are effective when EGFR detection yields unexpected results?

When EGFR detection with EGFR (Ab-678) Antibody produces unexpected results, systematic troubleshooting strategies should be implemented:

• No signal or weak signal issues:

  a. Sample preparation problems:

  • Ensure complete protein solubilization (EGFR is membrane-bound requiring detergent extraction)

  • Verify protein concentration using reliable methods (BCA/Bradford assay)

  • Check for protein degradation with Ponceau S staining of membrane

  b. Technical optimizations:

  • Decrease antibody dilution (try 1:500 instead of 1:1000)

  • Extend primary antibody incubation (overnight at 4°C)

  • Use more sensitive detection system (enhanced ECL)

  c. Biological considerations:

  • Confirm EGFR expression in your sample type (use A431 cells as positive control)

  • Check for EGFR downregulation by experimental treatments

  • Assess epitope accessibility (try alternative epitope antibodies)

• Multiple bands or unexpected molecular weight:

  a. EGFR variants identification:

  • 175 kDa: full-length EGFR

  • ~150-160 kDa: partially glycosylated forms

  • ~140 kDa: potential EGFRvIII or other variant

  • ~110 kDa: proteolytic fragment or alternative splice variant

  b. Technical investigative steps:

  • Test different sample preparation methods to minimize proteolysis

  • Perform peptide competition to identify specific versus non-specific bands

  • Compare with alternative EGFR antibodies targeting different epitopes

  c. Advanced validation:

  • Use mass spectrometry to identify unexpected bands

  • Perform siRNA knockdown to confirm specificity

  • Consider phosphorylation or other post-translational modifications

• High background or non-specific binding:

  a. Blocking improvements:

  • Change blocking agent (5% BSA instead of milk)

  • Extend blocking time (2 hours at room temperature)

  • Add 0.1% Tween-20 to antibody dilution buffer

  b. Washing optimization:

  • Increase washing stringency (0.1-0.3% Tween-20)

  • Extend wash durations (6 washes × 10 minutes each)

  • Use gentle agitation during washes

  c. Antibody handling:

  • Prepare fresh dilutions before each experiment

  • Pre-adsorb antibody against common cross-reactive proteins

  • Filter antibody dilution to remove aggregates

• Inconsistent results between experiments:

  a. Standardization approaches:

  • Develop detailed SOPs for sample preparation

  • Use consistent positive controls across experiments

  • Maintain antibody aliquots to avoid freeze-thaw cycles

  b. Quantification methods:

  • Use internal loading controls for normalization

  • Apply digital image analysis for objective quantification

  • Include calibration standards in each experiment

These systematic troubleshooting strategies address the most common technical challenges in EGFR detection, enabling researchers to generate consistent and interpretable results.

How can EGFR (Ab-678) Antibody support multiplexed detection systems for pathway analysis?

EGFR (Ab-678) Antibody can be effectively integrated into multiplexed detection systems for comprehensive pathway analysis through several methodological approaches:

• Multi-color Western blotting strategies:

  • Use EGFR (Ab-678) Antibody with fluorescently-labeled secondary antibodies

  • Combine with antibodies against downstream effectors (ERK, AKT, STAT3) using different fluorophores

  • Include phospho-specific antibodies with distinct fluorescent channels

  • Image using multi-channel fluorescence scanners for simultaneous detection

  • Quantify signal ratios to assess pathway activation states

• Reverse phase protein arrays (RPPA):

  • Spot multiple cell/tissue lysates on nitrocellulose-coated slides

  • Probe parallel arrays with EGFR (Ab-678) and antibodies against other pathway components

  • Use fluorescently-labeled secondary antibodies for detection

  • Analyze using automated image analysis software

  • Enables high-throughput analysis of hundreds of samples simultaneously

• Multiplex immunohistochemistry/immunofluorescence:

  • Apply sequential staining with EGFR (Ab-678) Antibody and other targets

  • Use tyramide signal amplification to allow multiple rounds of staining

  • Employ multispectral imaging systems to separate fluorophore signals

  • Perform digital pathology analysis for cell-by-cell quantification

  • Provides spatial context to pathway activation in tissue specimens

• Bead-based multiplex assays:

  • Couple EGFR (Ab-678) Antibody to spectrally distinct beads

  • Capture EGFR from lysates using antibody-conjugated beads

  • Detect with fluorescently-labeled detection antibodies

  • Analyze multiple analytes simultaneously using flow cytometry

  • Enables quantitative assessment of multiple RTK family members

• Single-cell analysis integration:

  • Combine with CyTOF (mass cytometry) using metal-tagged antibodies

  • Integrate with single-cell RNA sequencing data for multi-modal analysis

  • Correlate protein levels with transcriptomic profiles

  • Reveals cellular heterogeneity in EGFR pathway activation

  • Particularly valuable for tumor heterogeneity assessment

• Proximity ligation assays (PLA):

  • Use EGFR (Ab-678) Antibody with antibodies against interaction partners

  • Secondary antibodies with attached DNA oligonucleotides generate signal when targets are in close proximity

  • Allows visualization of protein-protein interactions in situ

  • Can detect EGFR dimerization, complex formation with downstream effectors

  • Provides spatial resolution of signaling events within cells

These multiplexed approaches enable comprehensive analysis of EGFR signaling networks, providing insights into pathway cross-talk, feedback mechanisms, and heterogeneity in response to therapeutic interventions.